$ARCT News
Last published 2d ago
- 2d agoARCTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCTURUS THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsThank you for joining us for this fireside chat with Arcturus Therapeutics. I'm Evan Wang, and with me are Joe Payne, President and Chief Executive Officer, and Alan Cohen, Chief Medical Officer. Thank you guys for being
- 2d agoARCTARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCTURUS THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsThank you for joining us for this fireside chat with Arcturus Therapeutics. I'm Evan Wang, and with me are Joe Payne, President and Chief Executive Officer, and Alan Cohen, Chief Medical Officer. Thank you guys for being
- 6d agoARCTArcturus Therapeutics Third Quarter 2026 Earnings Call - ARCTURUS THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsHello and welcome everyone joining today's Arcturus Therapeutics 3rd Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the
- 6d agoARCTArcturus Therapeutics Third Quarter 2026 Earnings Call - ARCTURUS THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsHello and welcome everyone joining today's Arcturus Therapeutics 3rd Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the
- 6d agoARCTArcturus Therapeutics Holdings Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoARCTArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it
- 1mo agoARCTARCTURUS PRESENTATION - ARCTURUS THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsHello, and welcome everyone joining today's Arcturus Therapeutics presentation. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask a question during the question-and-ans
- 1mo agoARCTArcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery PlatformBusiness WireARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple
- 1mo agoARCTArcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics PlatformBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
- 2mo agoARCTArcturus Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
- 3mo agoARCTArcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline ProgressBusiness WireARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to
- 3mo agoARCTArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
- 3mo agoARCTArcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth ConferenceBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
- 4mo agoARCTArcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic FibrosisBusiness WireStrategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights Arcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused
- 5mo agoARCTArcturus Therapeutics to Present at 2026 Jefferies Global Healthcare ConferenceBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the
- 6mo agoARCTArcturus Therapeutics First Quarter 2026 Earnings Call - Arcturus TherapeuticsEarnings Call TranscriptsHello and welcome everyone joining today's Arcturus Therapeutics first quarter 2026 earnings call. At this time all participants are in a listen only mode. Later you will have the opportunity to ask questions during the
- 6mo agoARCTArcturus Therapeutics First Quarter 2026 Earnings Call - Arcturus TherapeuticsEarnings Call TranscriptsHello and welcome everyone joining today's Arcturus Therapeutics first quarter 2026 earnings call. At this time all participants are in a listen only mode. Later you will have the opportunity to ask questions during the
- 6mo agoARCTArcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline ProgressBusiness WireInitiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on
- 6mo agoARCTArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it
- 6mo agoALNYARCTDNLIOTLC+1When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in BiotechGlobeNewswireAUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector
- 7mo agoARCT38TH ANNUAL ROTH CONFERENCE - ARCTURUS THERAPEUTICS HOLDINGS INCEarnings Call Transcriptsgood morning and thank you for joining us again for the 38th annual Roth conference my name is Adam Walsh I'm a senior research analyst with Roth covering the biotechnology sector our next presenter is Joe Payne CEO of A
- 8mo agoARCTArcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the
- 8mo agoARCTArcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Call - Arcturus TherapeuticsEarnings Call TranscriptsHello, and welcome everyone joining today's Arcturus Therapeutics 4th Quarter in Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask quest
- 8mo agoARCTArcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Call - Arcturus TherapeuticsEarnings Call TranscriptsHello, and welcome everyone joining today's Arcturus Therapeutics 4th Quarter in Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask quest
- 8mo agoARCTArcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Call - Arcturus TherapeuticsEarnings Call TranscriptsHello, and welcome everyone joining today's Arcturus Therapeutics 4th Quarter in Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask quest
- 8mo agoARCTArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline ProgressBusiness WireARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor
- 8mo agoARCTArcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious
- 11mo agoARCTArcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious
- 1y agoARCTArcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline ProgressBusiness WireEncouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start H1 2026 Additional cost reductions planned
- 1y agoARCTArcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious
- 1y agoARCTArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious
- 1y agoARCTArcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) ProgramBusiness WireARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants
- 1y agoARCTArcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious
- 1y agoARCTArcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call TranscriptEarnings Call Transcripts
- 1y agoARCTArcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline ProgressBusiness WireCystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810)
- 1y agoARCTArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency ProgramBusiness WireARCT-810 significantly and consistently reduces biomarker glutamine to levels within normal range 15N-ureagenesis data provide first evidence of an mRNA therapeutic improving urea cycle function Ammonia remained
- 1y agoARCTArcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) DeficiencyBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline ProgressBusiness WirePrioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year
- 1y agoARCTArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline ProgressBusiness WirePhase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted
- 1y agoARCTArcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTArcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025Business WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccinePR NewswireGlobal biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European...
- 1y agoARCTArcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
- 1y agoARCTMeiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19Business WireMeiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and
- 1y agoARCTArcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech ConferenceBusiness WireArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and